Gougerot-Falty Syndrome

Gougerot-Failt syndrome (multiple endocrine hyperparathyroidism type 2), a syndromic concept for a pathology associated with excessive stimulation of the parathyroid glands. The genetic basis of the disease is a mutation of the PTH1R gene on chromosome 3p21.[[1]](https://ru.wikipedia.org/wiki/%D0%93%D1%83%D0%B6%D0%B5%D1%80% D0 %BE-%D0%A4%D0% B0%D0%BB%D1 %8C%D1%82%D0%BE%D1%81%D1%) Synonym for “sialocephalosyringocyagnosis”. The main symptom is a combination of diabetes mellitus, osteoporosis with dental pathology and neurological disorders. The syndrome is named after the doctors who first described the disease, Joseph Gougereau and Ladislaus Failte.[2]

Gougereau-Falta syndrome is an endocrine disorder in which the parathyroid and thyroid glands malfunction, resulting in excess production of hormones, which can cause a variety of symptoms, including osteoporosis, weakness, weight gain, low blood pressure and elevated body temperature.

The syndrome was named after the Belgian physician Charles-Louis Goueret de Péréira, who described it in 1743. In 1917, German physician Ernest Wolfram Falta re-described this syndrome.

Guzhero - Falty syndrome affects no more than 5% of the population. The cause of the disease is a genetic factor. According to research, it occurs more often in women, especially between 35 and 50 years of age. However, these data do not allow us to accurately determine the frequency of the syndrome in the population. The presence of the disease may occur without visible symptoms; facial swelling, visual disturbances, menstrual irregularities, and anxiety are occasionally observed.